Sublingual Minoxidil Under-the-Tongue Tablet: Pivotal Phase 3 SAM-002 Clinical Trial Completes to Deliver Follicle Regrowth While Bypassing Liver Metabolism to Eliminate Heart Palpitations

For more than four decades, hair loss sufferers seeking systemic alternatives to greasy, alcohol-laden topical lotions have taken immediate-release blood pressure tablets off-label. However, swallowing minoxidil forces it through first-pass hepatic metabolism in the liver, converting large amounts into systemic minoxidil sulfate that circulates through cardiac tissue. This mechanism carries clinical risks of reflex tachycardia (heart racing), ankle swelling, and sudden blood pressure drops.

What Is It and How Does It Work?

• The Problem with Swallowed Oral Minoxidil: When a patient swallows a conventional oral minoxidil tablet, it travels down the esophagus and is absorbed through the stomach and intestines into the portal vein. The liver rapidly metabolizes a large fraction of the drug via hepatic sulfotransferase (SULT1A1) into minoxidil sulfate. This active sulfate metabolite then floods the general circulation, dilating peripheral vascular beds, lowering blood pressure, and forcing the heart into compensatory reflex tachycardia.
• The Sublingual Bypassing Route: Developed by Samson Clinical, the SLM tablet is a proprietary micro-engineered, fast-dissolving tablet placed directly under the tongue. Within 30 seconds, the formulation dissolves and absorbs directly across the thin non-keratinized sublingual mucosa into the internal jugular and superior vena cava system, bypassing the liver’s initial metabolic filter entirely.
• Selective Follicular Bio-Activation: By entering systemic circulation predominantly as unmetabolized parent minoxidil rather than circulating minoxidil sulfate, the drug remains biologically inert as it passes through the myocardium. Only when the parent molecule arrives at the scalp capillary bed and enters the hair follicle infundibulum is it converted into active minoxidil sulfate by local follicular SULT1A1 enzymes.
• Potassium Channel Hyperpolarization: Once generated locally inside dermal papilla cells, minoxidil sulfate opens ATP-sensitive potassium ($K_{\text{ATP}}$) channels. This triggers an intracellular potassium efflux that hyperpolarizes cell membranes, blocks calcium influx, relaxes microvascular smooth muscle, and prompts dormant hair follicle stem cells to re-enter active anagen growth, expanding miniaturized hair shafts into robust terminal fibers.

The Science: Clear Results from the 24-Week Phase 3 SAM-002 Clinical Trial

• Statistically Significant Hair Caliber and Density Gains: Computerized trichoscan imaging and phototrichograms confirmed that low-dose sublingual minoxidil induced statistically significant increases in non-vellus target area hair count and mean hair fiber diameter compared to placebo, directly reversing follicular miniaturization.
• Avoidance of Circulating Sulfate Surges: Pharmacokinetic monitoring revealed that sublingual delivery yielded lower peak concentrations ($C_{\max}$) of circulating minoxidil sulfate in systemic plasma compared to swallowed oral doses, ensuring targeted delivery to the scalp while sparing cardiac tissue.
• High Follicular Sulfation Efficacy: Because sublingual delivery avoids premature hepatic drug degradation, the bioavailability of active parent compound delivered to local scalp tissue remained high, maintaining robust anagen elongation across both the crown and frontotemporal zones.
• Clean Hemodynamic Safety Profile: Continuous 24-hour ambulatory blood pressure monitoring and resting electrocardiograms (ECGs) confirmed an absence of drug-related reflex tachycardia, fluid retention, or postural hypotension, matching the tolerability profile of inactive placebo tablets.

“Sublingual delivery bypasses hepatic first-pass metabolism to increase minoxidil sulfate in the hair follicle and hair growth, and at the same time reduces minoxidil sulfate in the circulation and avoids hemodynamic side effects such as palpitations… This establishes a convenient, safe, and highly effective alternative for patients with androgenetic alopecia.”

— Professor Rodney Sinclair, MBBS, MD, FACD, Professor of Medicine at the University of Melbourne and Founder of Samson Clinical.

When Will It Be Available?

• Current Stage: Completed pivotal 24-week Phase 3 randomized, double-blind, placebo-controlled clinical trials (SAM-002) with clinical database lock finalized.
• Timeline: Samson Clinical is preparing regulatory dossiers for market authorization submissions in priority territories (including Australia, the United States, and the United Kingdom). With Phase 3 data locked, regulatory reviews are progressing toward anticipated commercial prescription authorization by late 2027 to 2028.

How you can benefit from this treatment now

• The Shift from Off-Label Blood Pressure Pills to Calibrated Sublingual Formulations: This Phase 3 milestone demonstrates that hair restoration medicine is resolving the trade-off between messy topical scalp foams and risky oral blood pressure tablets. In the future, patients will take a tiny dissolvable tablet under the tongue that targets scalp follicles without straining the heart.
• Discuss Splitting or Compounding with Your Physician Today: If you currently take off-label oral minoxidil (such as 2.5 mg or 5 mg daily) and experience morning lightheadedness, swollen ankles, or heart racing, consult your prescribing doctor about dividing your swallowed dose into smaller micro-doses, or ask whether a specialized sublingual compounded formulation is clinically appropriate.
• Support Local Scalp Sulfotransferase (SULT1A1) Activity: Regardless of whether minoxidil is delivered sublingually or topically, it requires the scalp enzyme SULT1A1 to convert into its active form. Incorporating gentle weekly 0.5 mm shallow scalp micro-stamping or physician-prescribed low-strength topical tretinoin helps maintain follicular sulfotransferase expression and tissue permeability.
• Obtain Baseline Cardiovascular Screening Early: Before using any systemic potassium-channel opener, have your doctor check your baseline resting heart rate and blood pressure to ensure you do not have underlying cardiovascular conditions that could be aggravated by systemic vasodilation.
• Do Not Dissolve Swallowed Pills Under Your Tongue: Do not attempt to dissolve regular immediate-release oral minoxidil tablets under your tongue at home. Commercial generic blood pressure tablets are formulated with insoluble binders, starches, and talc that will not absorb across the oral mucosa, causing you to swallow bitter, uncalibrated particles and triggering the exact digestive absorption and cardiac spike you are trying to avoid.